These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30343636)

  • 1. An Assessment of Novel Biomarkers in Bone Metastatic Disease Using Multiplex Measurement and Multivariate Analysis.
    Windrichova J; Kucera R; Fuchsova R; Topolcan O; Fiala O; Svobodova J; Finek J; Slipkova D
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818807466. PubMed ID: 30343636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Windrichova J; Fuchsova R; Kucera R; Topolcan O; Fiala O; Finek J; Slipkova D; Karlikova M; Svobodova J
    Anticancer Res; 2016 Apr; 36(4):1973-8. PubMed ID: 27069189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Windrichova J; Fuchsova R; Kucera R; Topolcan O; Fiala O; Finek J; Slipkova D
    Anticancer Res; 2017 Mar; 37(3):1501-1505. PubMed ID: 28314325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
    Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
    Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
    Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?
    Bombardieri E; Martinetti A; Miceli R; Mariani L; Castellani MR; Seregni E
    Eur J Nucl Med; 1997 Nov; 24(11):1349-55. PubMed ID: 9371866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigations on bone metabolism of urological tumors forming metastases.
    Bichler KH; Petri E; Hub A; Kleinknecht S; Heidenreich A
    Urol Int; 1996; 56(2):61-8. PubMed ID: 8659012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone turnover markers and novel biomarkers in lung cancer bone metastases.
    Lang J; Zhao Q; He Y; Yu X
    Biomarkers; 2018 Sep; 23(6):518-526. PubMed ID: 29683727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum concentration of pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in the diagnosis of bone metastases].
    Koizumi M; Yamada Y; Takiguchi T; Suzuki C; Akashi T; Nomura E; Yamashita T; Ogata E
    Kaku Igaku; 1996 Jan; 33(1):77-84. PubMed ID: 8819718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
    Koizumi M; Yonese J; Fukui I; Ogata E
    J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
    Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
    Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.
    Jung K; Lein M; Stephan C; Von Hösslin K; Semjonow A; Sinha P; Loening SA; Schnorr D
    Int J Cancer; 2004 Sep; 111(5):783-91. PubMed ID: 15252851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
    Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients.
    Zissimopoulos A; Bantis A; Stellos K; Petrakis G; Matthaios D
    J BUON; 2008; 13(1):69-74. PubMed ID: 18404790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases.
    Kasoha M; Unger C; Solomayer EF; Bohle RM; Zaharia C; Khreich F; Wagenpfeil S; Juhasz-Böss I
    Clin Exp Metastasis; 2017 Dec; 34(8):479-490. PubMed ID: 29426963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: pitfalls of its use as an early surrogate marker for bone metastasis.
    Moseshvili E; Joseph DJ; Spry NA; Cohen RJ; Abreu A; Kautto A; Denham JW
    J Med Imaging Radiat Oncol; 2014 Aug; 58(4):497-502. PubMed ID: 24418365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A comparaison between the total PSA, the Gleason score and the bone scintiscan results for different age groups].
    Rusu D; Rusu V; Stefănescu C; Rusu M; Răileanu I; Stătescu AM
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):476-83. PubMed ID: 20700990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.